Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Early Detection of Pulmonary Fibrosis, 10/8/2021 8:00:00 AM - 10/8/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.
Presenter
Gary “Matt” Hunninghake, MD, MPH
Associate Professor of Medicine
Director, Interstitial Lung Disease Program
Brigham and Women's Hospital
Harvard Medical School
About our Presenter
Dr. Hunninghake is a pulmonologist, genetic epidemiologist, Associate Director for the Center for Pulmonary Functional Imaging, and the Director of the Interstitial Lung Disease Program at the Brigham and Women's Hospital. He completed medical school at the University of Iowa, residency and chief residency at Virginia Commonwealth University, and a pulmonary fellowship and a Masters of Public Health at Harvard.
Learning Outcome(s)
Participants will be able to discuss the clinical importance of targeted screening, careful identification of imaging abnormalities, and the overlap and differences between the genetic and genomic predictors of all stages of pulmonary fibrosis.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Gary Hunninghake, MD, MPH ~ is a consultant/advisor for Boehringer Ingelheim and Gerson Lehrman Group.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
Presenter
Gary “Matt” Hunninghake, MD, MPH
Associate Professor of Medicine
Director, Interstitial Lung Disease Program
Brigham and Women's Hospital
Harvard Medical School
About our Presenter
Dr. Hunninghake is a pulmonologist, genetic epidemiologist, Associate Director for the Center for Pulmonary Functional Imaging, and the Director of the Interstitial Lung Disease Program at the Brigham and Women's Hospital. He completed medical school at the University of Iowa, residency and chief residency at Virginia Commonwealth University, and a pulmonary fellowship and a Masters of Public Health at Harvard.
Learning Outcome(s)
Participants will be able to discuss the clinical importance of targeted screening, careful identification of imaging abnormalities, and the overlap and differences between the genetic and genomic predictors of all stages of pulmonary fibrosis.
Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.
* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.
* Gary Hunninghake, MD, MPH ~ is a consultant/advisor for Boehringer Ingelheim and Gerson Lehrman Group.
Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**.
* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).
** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
Bibliographic Material
See presentation for bibliographic sources to allow for further study.
